Therapeutic | Visilizumab |
Target | CD3E |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2000 |
INN Year Recommended | 2001 |
Companies Involved | PDL BioPharma |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Crohn's disease, Graft-versus-host disease, Psoriasis, Renal transplant rejection, Ulcerative colitis |
Notes |